Montreal, November 20, 2015 – ZoomMed Inc. (TSX Venture Exchange: ZMD), announces it has held its Annual and Special Meeting of Shareholders as at November 20, 2015.
The meeting was held for the purpose of:
- To receive the consolidated financial statements of ZoomMed for the fiscal year ended May 31, 2015 and the independent auditors’ report;
- To elect the board of directors composed of:
- Micheline Luneau
- Yves Marmet
- Nicolas Matziorinis
- Bruno Floriani
- Marie-Hélène Pinard
- Robert Powell
- To appoint Mazars Harel Drouin as the independent auditor and authorize the directors to fix their remuneration;
- To approve ZoomMed’s stock option plan, a 10% rolling stock option plan;
Also during the presentation done by the President and CEO, Yves Marmet, two topics were addressed concerning the press releases issued November 19, 2015 concerning the distribution rights of Rx Vigilance “Quick Glance” for the US market and the sell to Familiprix for $2,000,000 of its ownership rights of “PraxisLab”. For more details you can consult those press releases on our website.
For further information on ZoomMed, contact Mr. Yves Marmet, President and Chief Executive Officer (450) 678-5457, Ext 228, email@example.com or visit our Web Site; www.zoommed.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Statements made in this news release that are not historical facts are “forward-looking statements” and readers are cautioned that any such statements are not guarantees of future performance, and that actual developments or results, may vary materially from those in these “forward-looking” statement.